Statement: the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions.
Primary_evidence: Outcome Measurement:    Central Nervous System (CNS) Objective Response Rate   CNS objective response rate is the percentage of participants that achieve CNS complete or partial response as follows:   CNS complete response (CR) is achieved if all of the following are satisfied:   Complete resolution of all measurable (>= 1 cm in longest dimension [LD]) and non-measurable brain metastases   No new CNS lesions (defined as any new lesion >= 6 mm in LD)   Stable or decreasing steroid dose   No new/progressive tumor-related neurologic signs or symptoms   No progression of extra-CNS disease as assessed by RECIST   CNS partial response (PR) is achieved if all of the following are satisfied:   ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline   No progression on non-measurable lesions   No new CNS lesions (defined as any new lesion >/= 6 mm in LD)   Stable or decreasing steroid dose   No new/progressive tumor-related neurologic signs or symptoms   No progression of extra-CNS disease as assessed by RECIST   Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. Results 1:    Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+)   Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.   carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle   bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle   trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only   *8mg/kg loading dose in cycle 1 for some participants   HER-2: human epidermal growth factor receptor 2   Overall Number of Participants Analyzed: 38   Measure Type: Number   Unit of Measure: percentage of participants  63        (47 to 77)
Secondary_evidence: Outcome Measurement:    Objective Response Rate (ORR)   Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.   Time frame: Up to 2 years. Results 1:    Arm/Group Title: NKTR-102 14 Day   Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: percentage of subjects  28.6        (14.6 to 46.3) Results 2:    Arm/Group Title: NKTR-102 21 Days   Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: percentage of subjects  35        (14.6 to 46.3)